Evidence map›Paper›PMID 27083303›Full record

ArticleBehavioural brain research2016

FAAH inhibitor OL-135 disrupts contextual, but not auditory, fear conditioning in rats.

Michael A Burman, Kerribeth Szolusha, Rebecca Bind, Kristen Kerney, Dale L Boger, Edward J Bilsky

Abstract read
In one paragraph

Article in Behavioural brain research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. The effects of FAAH inhibition on the neural basis of anxiety-related processing in healthy male subjects: a randomized clinical trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021
    Trial
  2. Anxiety Modulation by Cannabinoids-The Role of Stress Responses and Coping.International journal of molecular sciences · 2023
    Review
  3. Review
  4. Review
  5. Article
  6. Iranian journal of pharmaceutical research : IJPR · 2020
    Article
  7. Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Michael A BurmanDepartment of Psychology, United States; Center for Excellence in the Neurosciences, University of New England, United States. Electronic address: mburman@une.edu.
Kerribeth SzolushaDepartment of Psychology, United States; Center for Excellence in the Neurosciences, University of New England, United States.
Rebecca BindCenter for Excellence in the Neurosciences, University of New England, United States.
Kristen KerneyCenter for Excellence in the Neurosciences, University of New England, United States.
Dale L BogerDepartment of Chemistry, The Scripps Research Institute, United States.
Edward J BilskyDepartment of Biomedical Sciences, United States; Center for Excellence in the Neurosciences, University of New England, United States.
University of New England · USScripps Research Institute · US

Funding

Modulating Signaling Endocannabinoids and Fatty Acid AmidesR37DA015648 · NIDA · SCRIPPS RESEARCH INSTITUTE, THE · PI DALE L BOGER · 2018 to 2026
$3.8M
Modulating Signaling Endocannabinoids and Fatty Acid AmidesR01DA015648 · NIDA · SCRIPPS RESEARCH INSTITUTE, THE · PI BOGER, DALE L · 2002 to 2017
$3.7M
Assessing the development of hippocampus-amygdala interactions during emotional lR15MH093950 · NIMH · UNIVERSITY OF NEW ENGLAND · PI BURMAN, MICHAEL A · 2012 to 2012
$405k
NIDA NIH HHS R01 DA015648NIDA NIH HHS R37 DA015648NIMH NIH HHS R15 MH093950
6 · The paper itself

Abstract

Anxiety disorders are among the most prevalent psychological disorders, have significant negative impacts on quality of life and the healthcare system, and yet effective treatments remain elusive. Manipulating the endocannabinoid system has demonstrated potential for treating anxiety, although the side effects of direct manipulations of cannabinoid receptors keeps them from widespread clinical use. Disrupting the degradation enzyme fatty acid amide hydrolase (FAAH) enhances endogenous signaling and may produce similar efficacy without the side effects. The current experiments examine the effects of low (5.6mg/kg) or moderate (10.0mg/kg) doses of OL-135, a FAAH inhibitor, on the acquisition and consolidation of classical fear conditioning, a common model of trauma-induced anxiety. The acquisition of contextual, but not auditory, fear conditioning was disrupted by both doses of OL-135. Shock reactivity was not affected. Due to the additional neural circuitry required for contextual, but not auditory, fear conditioning, these data suggest that endocannabinoid signaling outside the amygdala may be critical for a subset of fearful memories.

Indexed as

Acoustic StimulationAmidohydrolasesAnalysis of VarianceAnimalsConditioning, ClassicalDose-Response Relationship, DrugFatty Acid Amide HydrolasesFearMalePyridinesRatsRats, Sprague-Dawley1-oxo-1-(5-(2-pyridyl)-2-yl)-7-phenylheptaneAmidohydrolasesFatty Acid Amide HydrolasesPyridines

Identifiers

PMID27083303
PMCPMC4877211
OpenAlexW2340209243

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.